6 unknown. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Unknown 6 |
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells - Diffuse Large B Cell Lymphoma, Burkitt Lymphoma | Phase 3 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-09-14 | 2023-07-25 |
| Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies - High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 3 | Unknown | Shandong Provincial Hospital | 130 | 2021-04-15 | 2021-11-19 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX, R-CHOP; R-DA-EPOCH; R-HD MTX - High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 3 | Unknown | Shandong Provincial Hospital | 160 | 2021-03-01 | 2021-12-21 |
| ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning - Mantle Cell Lymphoma | Phase 3 | Unknown | Prof. Dr. M. Dreyling (co-chairman) | 870 | 2016-07-01 | 2017-12-19 |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients Lenalidomide - MANTLE CELL LYMPHOMA | Phase 3 | Unknown | Fondazione Italiana Linfomi - ETS | 300 | 2010-05-01 | 2018-02-09 |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL Rituximab, High dose Ara-C, Dexamethasone - Mantle Cell Lymphoma | Phase 3 | Unknown | Prof. Dr. M. Dreyling (co-chairman) | 128 | 2009-05-09 | 2017-03-07 |
Lymphoma, Mantle-Cell (6) · Lymphoma, Large B-Cell, Diffuse (3) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Recurrence (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Disease Attributes (2) · Lymphoma, B-Cell (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · DNA Virus Infections (1)
Rituximab (2) · Bortezomib (1) · Cytarabine (1) · Dexamethasone (1) · Lenalidomide (1) · Maintenance (1) · Neoadjuvant Therapy (1) · Tromethamine (1) · ibrutinib (1)
Prof. Dr. M. Dreyling (co-chairman) (2) · Shandong Provincial Hospital (2) · Fondazione Italiana Linfomi - ETS (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (3) · Germany (2) · Italy (2) · Denmark (1) · France (1) · Norway (1) · Portugal (1) · Sweden (1)
Xin Wang, PhD (2) · Martin Dreyling, MD (1) · Martin Dreyling, Prof. (1) · Sergio Cortelazzo, MD (1) · Yu Hu (1)
PMID 29472356, PMID 31537689, PMID 31633999, PMID 33357480, PMID 35008361, PMID 36485104, PMID 38678093, PMID 38705160, PMID 39808795, PMID 41123227, PMID 42134356
2009 (1)